Linked Life Data

18344723

Source:http://linkedlifedata.com/resource/pubmed/id/18344723

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-3-17
pubmed:abstractText
Weight gain and other metabolic disturbances have now become discouraging, major side effects of atypical antipsychotic drugs (AAPDs). The novel strategies required to counteract these serious consequences, however, should avoid modulating the activities of the neurotransmitter receptors involved because those receptors are the therapeutic targets of AAPDs. Adenosine monophosphate-activated protein kinase is an enzyme that plays a pivotal role in energy homeostasis. We hypothesized that alpha-lipoic acid (ALA), which is known to modulate adenosine monophosphate-activated protein kinase activity in the hypothalamus and peripheral tissues, would ameliorate AAPD-induced weight gain. We describe the case series of a 12-week ALA trial in schizophrenia patients treated with AAPDs. Two of 7 enrolled subjects were dropped from the study because of noncompliance and demand for new medication to treat depressive symptoms, respectively. The mean (SD) weight loss was 3.16 (3.20) kg (P = 0.043, last observation carried forward; median, 3.03 kg; range, 0-8.85 kg). On average, body mass index showed a significant reduction (P = 0.028) over the 12 weeks. During the same period, a statistically significant reduction was also observed in total cholesterol levels (P = 0.042), and there was a weak trend toward the reduction in insulin resistance (homeostasis model assessment of insulin resistance) (P = 0.080). Three subjects reported increased energy subjectively. The total scores on the Brief Psychiatric Rating Scale and the Montgomery-Asberg Depression Rating Scale did not vary significantly during the study. These preliminary data suggest the possibility that ALA can ameliorate the adverse metabolic effects induced by AAPDs. To confirm the benefits of ALA, more extended study is warranted.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0271-0749
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
138-46
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:18344723-Adult, pubmed-meshheading:18344723-Antioxidants, pubmed-meshheading:18344723-Antipsychotic Agents, pubmed-meshheading:18344723-Appetite, pubmed-meshheading:18344723-Blood Glucose, pubmed-meshheading:18344723-Body Mass Index, pubmed-meshheading:18344723-Brief Psychiatric Rating Scale, pubmed-meshheading:18344723-Cholesterol, HDL, pubmed-meshheading:18344723-Cholesterol, LDL, pubmed-meshheading:18344723-Depression, pubmed-meshheading:18344723-Fasting, pubmed-meshheading:18344723-Fatty Acids, Nonesterified, pubmed-meshheading:18344723-Female, pubmed-meshheading:18344723-Humans, pubmed-meshheading:18344723-Insulin, pubmed-meshheading:18344723-Insulin Resistance, pubmed-meshheading:18344723-Male, pubmed-meshheading:18344723-Obesity, pubmed-meshheading:18344723-Recurrence, pubmed-meshheading:18344723-Schizophrenia, pubmed-meshheading:18344723-Thioctic Acid, pubmed-meshheading:18344723-Triglycerides, pubmed-meshheading:18344723-Weight Loss
pubmed:year
2008
pubmed:articleTitle
A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia.
pubmed:affiliation
Department of Psychiatry and Institute of Behavioral Science in Medicine, College of Medicine, Yonsei University, Seoul, Republic of Korea.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't